Picture of MaxCyte logo

MXCT MaxCyte News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - AIM Block Admission Return / Total Voting Rights





 




RNS Number : 6728D
MaxCyte, Inc.
20 February 2020
 

SCHEDULE 6


AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS

 

Please ensure the entries on this return are typed

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From  17 November 2018                          To   20 February 2020

 

d. Number and class of securities not issued under scheme

 

415,759 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

96,496 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

319,263 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional blocklisting application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

57,403,583 (51,444,847 MXCT.L and 5,958,736 MXCS.L)

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

 

Date  

 

20 February 2020


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCURRWRRNUUUAR

Recent news on MaxCyte

See all news